Top Markets
#1 Black Phoenix Black Phoenix +21,534.66%
#2 Nesa Nesa +729.63%
#3 Kinesis Silver Kinesis Silver +54.95%
#4 BNB Attestation Service BNB Attestation Service +26.00%
#5 QuantixAI QuantixAI +24.05%
#6 EXOD EXOD +22.78%
#7 Pons Pons +20.03%
#8 Biconomy Biconomy +19.45%
#9 Derive Derive +18.54%
#10 Cash Cat Cash Cat +16.88%
Coin of the day
Black Phoenix Black Phoenix
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
Suzhou Zelgen Biopharmaceuticals Co., Ltd. Suzhou Zelgen Biopharmaceuticals Co., Ltd.

Suzhou Zelgen Biopharmaceuticals Co., Ltd.

688266
Classement en actions #3838
Suzhou Zelgen Biopharmaceuticals Co., Ltd., together with its subsidiaries,... Suzhou Zelgen Biopharmaceuticals Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, and distribution of medicines in the People's Republic of China. The company offers donafenib tablets for hepatocellular carcinoma and iodine-refractory differentiated thyroid cancer; recombinant human thrombin for hemostasis; and jacktinib tablets for intermediate and high-risk myelofibrosis. It also develops drug candidates in the NDA, Phase III, or registration clinical trial stages, such as gecacitinib hydrochloride tablets for severe alopecia areata, moderate to severe atopic dermatitis, ankylosing spondylitis, ruxolitinib-intolerant and relapsed/refractory myelofibrosis, moderate to severe plaque psoriasiste, idiopathic pulmonary fibrosis, severe alopecia areata, nonsegmental vitiligo, and myelofibrosis; and recombinant human thyroid-stimulating hormone for injection. In addition, the company is developing drug candidates in Phase I/II clinical trial stages consisting of donafenib tablets for liver cancer and anti-tumor immunotherapy; gecacitinib hydrochloride cream for mild to moderate alopecia areata and atopic dermatitis, and nonsegmental vitiligo; ZG19018 and ZG2001 tablets for KRAS G12C and KRAS mutation late-stage solid tumors; and ZG005, ZGGS18, ZGGS15, ZG0895, and ZG006 powders for injections for late-stage solid tumors. Further, it develops pre-clinical drug candidates, including ZG1905 for topical bleeding; and ZGGS001 and GS11 powders for injections for late-stage tumors. The company’s products are used in multiple therapeutic areas, such as tumors, bleeding and blood diseases, and immune inflammatory diseases. Suzhou Zelgen Biopharmaceuticals Co., Ltd. was founded in 2009 and is based in Kunshan, the People's Republic of China.
Prix de l'action
$17.35
Capitalisation boursière
$4.59B
Changement (1 jour)
0.59%
Changement (1 an)
14.36%
Pays
CN
Échange Suzhou Zelgen Biopharmaceuticals Co., Ltd. (688266)

Catégorie

Healthcare
Bénéfices pour Suzhou Zelgen Biopharmaceuticals Co., Ltd. (688266)
Bénéfices en 2026 TTM : 0
Selon les derniers rapports financiers de Suzhou Zelgen Biopharmaceuticals Co., Ltd., les bénéfices actuels de l'entreprise sont de 0. En 2026, l'entreprise a réalisé un bénéfice de 0, égal à celui de 2026 qui était de 0. Les bénéfices affichés sur cette page correspondent aux bénéfices avant intérêts et impôts, appelés aussi EBIT.
Historique des bénéfices pour Suzhou Zelgen Biopharmaceuticals Co., Ltd. de 2026 à 2026
Bénéfices à la fin de chaque année
Année Bénéfices Changez
Pas assez de données pour les dates fournies.
Bénéfices des entreprises similaires ou concurrentes
Entreprise Bénéfices Différence de bénéfices Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
$-4.02B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH